tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ASND Stock Latest News

Ascendis Pharma’s Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating
RatingsAscendis Pharma’s Yorvipath Shows Long-Term Kidney Benefits, Boosting Buy Rating
3d ago
ASND
Ascendis Pharma’s Yorvipath: Strong Phase 3 Results and Market Adoption Drive Buy Rating
PremiumRatings
Ascendis Pharma’s Yorvipath: Strong Phase 3 Results and Market Adoption Drive Buy Rating
3d ago
ASND
Ascendis Pharma announces new data from PaTHway Trial at ENDO 2025
PremiumThe Fly
Ascendis Pharma announces new data from PaTHway Trial at ENDO 2025
4d ago
ASND
Ascendis Pharma’s Cancer Study Termination: Implications for Investors
PremiumCompany Announcements
Ascendis Pharma’s Cancer Study Termination: Implications for Investors
7d ago
ASND
Ascendis Pharma price target raised to $243 from $213 at Citi
PremiumThe Fly
Ascendis Pharma price target raised to $243 from $213 at Citi
7d ago
ASND
Ascendis Pharma Grants Warrants to Employees to Boost Engagement
PremiumCompany AnnouncementsAscendis Pharma Grants Warrants to Employees to Boost Engagement
9d ago
6K
ASND
Positive Outlook for Ascendis Pharma Driven by Yorvipath’s Growing Adoption and Revenue Potential
Premium
Ratings
Positive Outlook for Ascendis Pharma Driven by Yorvipath’s Growing Adoption and Revenue Potential
9d ago
ASND
Ascendis Pharma assumed with an Overweight at Morgan Stanley
Premium
The Fly
Ascendis Pharma assumed with an Overweight at Morgan Stanley
16d ago
ASND
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
PremiumCompany Announcements
Ascendis Pharma Closes Warrant Exercise Window, Boosts Share Capital
21d ago
6K
ASND
Ascendis Pharma’s Competitive Edge in Achondroplasia Treatment: Buy Rating Supported by TransCon CNP’s Potential and Yorvipath Launch
PremiumRatings
Ascendis Pharma’s Competitive Edge in Achondroplasia Treatment: Buy Rating Supported by TransCon CNP’s Potential and Yorvipath Launch
21d ago
ASND
Ascendis Pharma price target raised to $224 from $215 at Oppenheimer
PremiumThe Fly
Ascendis Pharma price target raised to $224 from $215 at Oppenheimer
1M ago
ASND
Ascendis Pharma Grants Employee Warrants to Boost Retention
PremiumCompany Announcements
Ascendis Pharma Grants Employee Warrants to Boost Retention
1M ago
6K
ASND
Ascendis Pharma’s TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating
PremiumRatingsAscendis Pharma’s TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating
1M ago
ASND
Ascendis Pharma’s Promising Growth Potential Backed by Strong Trial Results and Product Launches
Premium
Ratings
Ascendis Pharma’s Promising Growth Potential Backed by Strong Trial Results and Product Launches
1M ago
ASND
Ascendis Pharma Reveals Promising Interim Results from COACH Trial for Achondroplasia
Premium
Company Announcements
Ascendis Pharma Reveals Promising Interim Results from COACH Trial for Achondroplasia
1M ago
6K
ASND
Ascendis Pharma Reports Promising Interim Results from COACH Trial
PremiumCompany Announcements
Ascendis Pharma Reports Promising Interim Results from COACH Trial
1M ago
6K
ASND
Positive Outlook for Ascendis Pharma: Buy Rating Affirmed on Promising Clinical Trial Results and Future Prospects
PremiumRatings
Positive Outlook for Ascendis Pharma: Buy Rating Affirmed on Promising Clinical Trial Results and Future Prospects
1M ago
ASND
Ascendis Pharma price target raised to $216 from $201 at BofA
PremiumThe Fly
Ascendis Pharma price target raised to $216 from $201 at BofA
1M ago
ASND
Ascendis Pharma announces interim analysis results from COACH trial
PremiumThe Fly
Ascendis Pharma announces interim analysis results from COACH trial
1M ago
ASND
Ascendis Pharma’s Promising Outlook: FDA Priority Review and Market Performance Drive Buy Rating
PremiumRatingsAscendis Pharma’s Promising Outlook: FDA Priority Review and Market Performance Drive Buy Rating
1M ago
ASND
Ascendis Pharma price target raised to $201 from $196 at BofA
Premium
The Fly
Ascendis Pharma price target raised to $201 from $196 at BofA
2M ago
ASND
Ascendis Pharma’s TransCon CNP Receives FDA Priority Review
Premium
Company Announcements
Ascendis Pharma’s TransCon CNP Receives FDA Priority Review
2M ago
6K
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >